Valeritas is a technology company.
Valeritas has raised $245.0M across 3 funding rounds.
Valeritas has raised $245.0M in total across 3 funding rounds.
Valeritas has raised $245.0M in total across 3 funding rounds.
Valeritas's investors include Pitango Venture Capital.
Valeritas was a commercial-stage medical technology company focused on developing and commercializing innovative insulin delivery technologies specifically for adults with Type 2 diabetes. Its flagship product, V-Go, was a discreet, wearable, fully disposable basal-bolus insulin delivery device designed to simplify insulin therapy by mimicking the body's natural insulin delivery without the need for electronics, batteries, or programming. Valeritas aimed to improve health outcomes and quality of life for patients by providing an affordable, easy-to-use alternative to multiple daily insulin injections[1][2][3].
Founded in 2006 and headquartered in Bridgewater, New Jersey, Valeritas developed V-Go to address the challenges faced by Type 2 diabetes patients requiring insulin therapy, such as complexity, inconvenience, and adherence issues. The company’s innovation was notable for its injection-molded cartridge technology and real-time tracking capabilities under development. Despite its promising technology and market focus, Valeritas filed for Chapter 11 bankruptcy and ceased operations in mid-2020[1][2].
Valeritas was founded in 2006 with the mission to improve diabetes management through technology tailored to Type 2 diabetes patients. The idea emerged from the need to simplify basal-bolus insulin therapy, which traditionally involves multiple daily injections that can be cumbersome and error-prone. The founders and early team focused on creating a wearable device that could deliver insulin continuously and discreetly, improving adherence and glucose control. Early traction was achieved with the commercial launch of V-Go, which gained recognition as the only basal-bolus insulin delivery device specifically designed for Type 2 diabetes patients in the U.S. market[1][2].
Valeritas operated at the intersection of medical technology and chronic disease management, riding the trend toward wearable health devices and personalized medicine. The timing was critical as the global burden of Type 2 diabetes was rising, creating demand for more patient-friendly insulin delivery solutions. Market forces such as increasing healthcare costs, patient preference for non-invasive treatments, and advances in polymer and wearable tech supported Valeritas’ approach. By focusing on Type 2 diabetes—a large and underserved segment in insulin therapy—Valeritas contributed to shifting diabetes care toward more convenient, technology-enabled management[2][3].
Although Valeritas ceased operations in 2020, its innovation in wearable insulin delivery highlighted important trends in diabetes care: simplification of complex therapies, patient-centric design, and integration of real-time monitoring. Future companies building on this legacy will likely focus on combining wearable devices with digital health platforms for enhanced adherence and outcomes. The broader ecosystem continues to evolve toward seamless, minimally invasive diabetes management solutions, driven by patient demand and technological advances in materials and connectivity.
Valeritas’ story underscores the challenges and opportunities in commercializing medical technology for chronic diseases, emphasizing the need for robust business models alongside innovative products. Its pioneering work with V-Go remains a reference point for wearable insulin delivery innovation[1][2][3].
Valeritas has raised $245.0M across 3 funding rounds. Most recently, it raised $45.0M Series D in July 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2014 | $45.0M Series D | Pitango Venture Capital | |
| Sep 1, 2011 | $150.0M Series C | Pitango Venture Capital | |
| Sep 1, 2008 | $50.0M Series A | Pitango Venture Capital |